Koninklijke Philips NV Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/14/2026)
| Balance Sheet | Total Assets | 26,944,000,000.00 | ROE | 40.67 % |
| Balance Sheet | Total Equity | 10,957,000,000.00 | ROA | 3.33 % |
| Cashflow | Capital Expenditures | -269,000,000.00 | P/FCF | 23.95 |
| Cashflow | Free Cash Flow | 903,000,000.00 | – | – |
| Cashflow | Operating Cash Flow | 1,172,000,000.00 | P/CF | 18.45 |
| Income | Earnings per Share (diluted) | 0.93 | Div. Yield | 3.78 % |
| Income | Net Income | 896,000,000.00 | P/E | 24.16 |
| Income | Shares Outstanding | 962,503,000.00 | P/B | 1.97 |
| Income | Total Revenue | 17,834,000,000.00 | P/S | 1.21 |
Ratios calculated on: 10/14/2026
Company Description
Royal Philips of the Netherlands is a leading health technology company focused on improving peoples health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.philips.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more